![]() In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. Exacerbations, in some cases serious, occurred in COSENTYX treated subjects during clinical trials Monitor patients closely for signs and symptoms of active TB during and after treatment.Ĭaution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent orĪctive TB in whom an adequate course of treatment cannot be confirmed. ![]() Initiate treatment of latent TB prior to administering COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Pre-treatment Evaluation for TuberculosisĮvaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. In the postmarketing setting, serious and some fatal infections have been reported in patients receiving COSENTYX.Įxercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. The incidence of some types of infections appeared to be dose-dependent in clinical studies. ![]() A similar increase in risk of infection was seen in placebo-controlled trials in subjects with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In placebo-controlled clinical trials in subjects with moderate to severe plaque psoriasis, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. Cases of anaphylaxis have been reported during treatment with COSENTYX.ĬOSENTYX may increase the risk of infections. Secukinumab or to any of the excipients in COSENTYX. Plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.ĬOSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.ĬOSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).ĬOSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA)ĬOSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.ĬOSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to COSENTYX ® (secukinumab) is indicated for the treatment of moderate to severe
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |